The starting point for this project is the recent finding that women who experience miscarriages or terminations of pregnancy before theuir first birth have an increased risk of having a preterm (premature) infant. These findings have prompted a re-evaluation of the relationship between the number of pregnancies a women has had and the likely outcome in later pregnancies. It will take into account the stage at which prior pregnancies ended, what the outcomes of the pregnancies were (birth, healt ....The starting point for this project is the recent finding that women who experience miscarriages or terminations of pregnancy before theuir first birth have an increased risk of having a preterm (premature) infant. These findings have prompted a re-evaluation of the relationship between the number of pregnancies a women has had and the likely outcome in later pregnancies. It will take into account the stage at which prior pregnancies ended, what the outcomes of the pregnancies were (birth, health baby, death, baby with a birth defect, termination, miscarriage etc), as well as factors such as maternal age, in relation to the risks in subsequent pregnancies. The expected outcomes and significance of the study are: * new evidence about factors causing adverse outcomes of pregnancy; * better information on the risk of recuurence of common birth defects; * more precise information on risks of adverse pregnancy outcomes for users and planners of maternity services.Read moreRead less
Anogenital Human Papillomavirus Infection And Its Outcomes In Men
Funder
National Health and Medical Research Council
Funding Amount
$333,433.00
Summary
Anal human papillomavirus (HPV) infection is common in homosexual men. Low risk types cause anal warts and high risk types of HPV cause anal cancer. This study will determine incidence and risk factors for HPV infection in a cohort of young homosexual men, the association of anal warts treatment with HIV risk, and the specific association of HPV subtypes with anal cancer. The findings of this research will help delineate the potential benefits of HPV vaccination in this population.
Understanding The Health Effects Of Biomass Smoke In Australian Towns And Cities
Funder
National Health and Medical Research Council
Funding Amount
$172,392.00
Summary
Wildfires have become more frequent and severe the world over and the health impacts of the associated air pollution is a major gap in the current evidence. Working with lead agencies in air quality regulation, public health and fire management I will examine and compare the health effects of air pollution from deliberate burns, bushfires, wood heaters and other sources of air pollution. The research will focus on respiratory and heart disease to inform public health and individual patient care.
Metabolic And Hormonal Pathways In Gynecological Cancer - Epidemiological Studies Of Risk And Survival
Funder
National Health and Medical Research Council
Funding Amount
$288,275.00
Summary
Metabolic and hormonal factors probably play a role in a womans chance of developing and surviving gynecological cancer, but the exact mechanisms are unclear. This project will use questionnaire information, blood and tumour samples of over 5,000 Australian women to examine the mechanisms leading to cancer development and survival among women with uterine and ovarian cancer, the two commonest female reproductive cancers. Results will help plan primary prevention strategies and care.
David Whiteman is a medical epidemiologist with a special interest in the causes, diagnosis, prevention and treatment of cancer. His work has focussed on melanoma and skin cancer, and more recently, on cancers of the upper gastro-intestinal tract.
Genetic And Environmental Epidemiology Of Early-onset Melanoma In The Australian Melanoma Family Study
Funder
National Health and Medical Research Council
Funding Amount
$412,210.00
Summary
This project will investigate the genetic and environmental causes of melanoma, especially melanoma developing under the age of 40 in Australian families. This project will help to identify which people are at greatest risk of developing melanoma, by identifying the genes involved in melanoma development and the contribution of environmental and lifestyle factors to the disease. We will also determine how much hereditary factors contribute to melanoma risk.
Antiplatelets For Prevention Of Pre-eclampsia: An Individual Patient Data Review
Funder
National Health and Medical Research Council
Funding Amount
$274,000.00
Summary
High blood pressure is a common complication of pregnancy affecting ~20,000 Australian women each year. Although most women and their babies do well, pre-eclampsia, defined as high blood pressure together with protein in the urine is a more serious problem. Severe pre-eclampsia is associated with 10-15% of maternal deaths. Fetal and newborn baby deaths are also increased. Mother and baby morbidity is high principally due to the associated complications in pregnancy, increased obstetric intervent ....High blood pressure is a common complication of pregnancy affecting ~20,000 Australian women each year. Although most women and their babies do well, pre-eclampsia, defined as high blood pressure together with protein in the urine is a more serious problem. Severe pre-eclampsia is associated with 10-15% of maternal deaths. Fetal and newborn baby deaths are also increased. Mother and baby morbidity is high principally due to the associated complications in pregnancy, increased obstetric interventions, fetal growth restriction and preterm birth. As yet we have no safe and effective way of preventing this life threatening condition. Aggregation of platelets (involved in blood clotting) is known to be part of the disease and could lead to the disturbances in the circulation of the mother and the placenta. Antiplatelet agents, low dose aspirin in particular, might prevent or delay the development of pre-eclampsia. Some trials and a Cochrane systematic review of all trials (involving over 30,000 women) suggest that pre-eclampsia, preterm birth and perinatal death could be reduced. However, it is still not clear which women will benefit, when in pregnancy the treatment should start and what dose of aspirin is both effective and safe. This proposed individual patient data review in which data on all women who have been entered in trials is gathered from the original investigators, including missing information on potential harms. This proposal represents a good investment of resources to obtain the information needed by women and health professional to make decisions about the use of aspirin. International investigators from all the primary trials have already formed a collaboration to oversee the project: the Perinatal Antiplatelet Review of International Studies (PARIS) Collaboration Furthermore, working through an international collaboration will ensure the highest quality in data availability, as well endorsement and implementation of the results in practice.Read moreRead less